BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Generalized Anxiety Disorder readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Generalized Anxiety D
 isorder\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06480383-708@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06480383)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 16 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06480383
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701903-708@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06701903)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized
  Anxiety Disorder\nEstimated primary completion: 14 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06701903
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767903-857@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20281025
DTEND;VALUE=DATE:20281026
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07767903)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults Wi
 th Generalized Anxiety Disorder\nEstimated primary completion: 25 October 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07767903
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759128-857@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20281206
DTEND;VALUE=DATE:20281207
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07759128)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults Wit
 h Generalized Anxiety Disorder\nEstimated primary completion: 6 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07759128
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786454-857@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07786454)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Safety and Tolerability of SEP-363856 in Adults With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 26 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07786454
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807865-708@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20300218
DTEND;VALUE=DATE:20300219
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07807865)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as 
 an Additional Treatment in Participants With Generalized Anxiety Disorder 
 (GAD)\nEstimated primary completion: 18 February 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/deulumateperone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07807865
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856420-708@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20300920
DTEND;VALUE=DATE:20300921
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07856420)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Partic
 ipants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Resp
 onse to GAD Treatment\nEstimated primary completion: 20 September 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07856420
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
